MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-10-2025
Inovio Pharmaceuticals DSO Ratio 2011-2026 | INO
Annual DSO Ratio Inovio Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 1.91 K | 474 | 180 | 48.6 | 56.1 | 171 | 66 | 97.9 | 89.5 | 76.8 | 18.9 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.91 K | 18.9 | 290 |
Quarterly DSO Ratio Inovio Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 1.75 K | - | - | 1.96 K | - | - | - | - | 705 | - | 34.5 | 494 | 2.17 K | - | 2.8 K | 3.85 K | 1.69 K | 1.82 K | 1.89 K | 1.59 K | 2.11 K | 109 | 100 | 84.6 | 293 | 121 | 536 | 584 | 278 | 62.3 | 207 | 26.8 | 96 | 170 | 115 | 233 | 130 | 112 | 27.7 | 127 | 89.5 | 104 | 139 | 67.3 | 118 | 173 | 31.8 | 383 | 130 | 66.8 | 88.7 | 174 | 35 | 26.1 | 16.2 | 17.6 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.85 K | 16.2 | 582 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
Exelixis
EXEL
|
43.4 | $ 48.43 | 9.03 % | $ 13.2 B | USA |
 |
Fortress Biotech
FBIO
|
115 | $ 2.56 | 3.96 % | $ 71.4 M | USA |
 |
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | USA |
 |
Galapagos NV
GLPG
|
56.5 | $ 28.78 | 1.36 % | $ 2.69 B |  Belgium |
 |
Genmab A/S
GMAB
|
97.9 | $ 27.93 | 1.41 % | $ 17.2 B |  Danmark |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | USA |
 |
Ionis Pharmaceuticals
IONS
|
20.5 | $ 76.96 | 2.27 % | $ 12.3 B | USA |
 |
Kamada Ltd.
KMDA
|
103 | $ 8.3 | 1.1 % | $ 260 M |  Israel |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
77.8 | $ 229.83 | -1.06 % | $ 4.2 B | USA |
 |
INmune Bio
INMB
|
19.9 K | $ 1.52 | -1.3 % | $ 37.6 M | USA |
 |
Liquidia Corporation
LQDA
|
65.5 | $ 41.84 | 4.26 % | $ 3.6 B | USA |
 |
Mirum Pharmaceuticals
MIRM
|
70.6 | $ 107.42 | 1.52 % | $ 5.39 B | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
37.5 | $ 22.32 | -0.13 % | $ 3.7 B | USA |
 |
MannKind Corporation
MNKD
|
26.2 | $ 3.68 | 28.5 % | $ 1.12 B | USA |
 |
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | USA |
 |
Esperion Therapeutics
ESPR
|
99.7 | $ 3.13 | 0.55 % | $ 651 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
28.1 | $ 3.47 | -8.44 % | $ 5.71 M | Israel |
 |
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M |  Canada |
 |
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
13.6 | - | - | $ 867 M |  Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
0.114 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
14.7 | - | -0.23 % | $ 916 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
106 | $ 23.86 | 1.88 % | $ 3.04 B | USA |
 |
Puma Biotechnology
PBYI
|
68.5 | $ 7.5 | 2.04 % | $ 375 M | USA |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |